Tags

Type your tag names separated by a space and hit enter

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).
Diabetes Obes Metab. 2008 Dec; 10(12):1239-47.DO

Abstract

AIM

To determine if therapeutic management programmes for type 2 diabetes that include self-monitoring of blood glucose (SMBG) result in greater reductions in glycated haemoglobin (HbA1c) compared with programmes without SMBG in non-insulin requiring patients.

METHODS

Multicentre, randomized, parallel-group trial. A total of 610 patients were randomized to SMBG or non-SMBG groups. Patients in both groups received the same oral antidiabetic therapy using a gliclazide modified release (MR)-based regimen for 27 weeks. The primary efficacy end-point was the difference between groups in HbA1c at the end of observation.

RESULTS

A total of 610 patients were randomized: 311 to the SMBG group and 299 to the non-SMBG group. HbA1c decreased from 8.12 to 6.95% in the SMBG group and from 8.12 to 7.20% in the non-SMBG group; between-group difference was 0.25% (95% CI: 0.06, 1.03; p = 0.0097). Symptoms suggestive of mild to moderate hypoglycaemia was the most commonly reported adverse event, reported by 27 (8.7%) and 21 (7.0%) patients in the SMBG and non-SMBG groups, respectively; the incidence of symptomatic hypoglycaemia was lower in the SMBG group.

CONCLUSION

In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c.

Authors+Show Affiliations

Department of Medicine, University of Birmingham, Birmingham Heartlands Hospital, Birmingham, UK. anthony.barnett@heartofengland.nhs.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18494813

Citation

Barnett, A H., et al. "The Efficacy of Self-monitoring of Blood Glucose in the Management of Patients With Type 2 Diabetes Treated With a Gliclazide Modified Release-based Regimen. a Multicentre, Randomized, Parallel-group, 6-month Evaluation (DINAMIC 1 Study)." Diabetes, Obesity & Metabolism, vol. 10, no. 12, 2008, pp. 1239-47.
Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab. 2008;10(12):1239-47.
Barnett, A. H., Krentz, A. J., Strojek, K., Sieradzki, J., Azizi, F., Embong, M., Imamoglu, S., Perusicová, J., Uliciansky, V., & Winkler, G. (2008). The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes, Obesity & Metabolism, 10(12), 1239-47. https://doi.org/10.1111/j.1463-1326.2008.00894.x
Barnett AH, et al. The Efficacy of Self-monitoring of Blood Glucose in the Management of Patients With Type 2 Diabetes Treated With a Gliclazide Modified Release-based Regimen. a Multicentre, Randomized, Parallel-group, 6-month Evaluation (DINAMIC 1 Study). Diabetes Obes Metab. 2008;10(12):1239-47. PubMed PMID: 18494813.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). AU - Barnett,A H, AU - Krentz,A J, AU - Strojek,K, AU - Sieradzki,J, AU - Azizi,F, AU - Embong,M, AU - Imamoglu,S, AU - Perusicová,J, AU - Uliciansky,V, AU - Winkler,G, Y1 - 2008/05/20/ PY - 2008/5/23/pubmed PY - 2009/7/28/medline PY - 2008/5/23/entrez SP - 1239 EP - 47 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 10 IS - 12 N2 - AIM: To determine if therapeutic management programmes for type 2 diabetes that include self-monitoring of blood glucose (SMBG) result in greater reductions in glycated haemoglobin (HbA1c) compared with programmes without SMBG in non-insulin requiring patients. METHODS: Multicentre, randomized, parallel-group trial. A total of 610 patients were randomized to SMBG or non-SMBG groups. Patients in both groups received the same oral antidiabetic therapy using a gliclazide modified release (MR)-based regimen for 27 weeks. The primary efficacy end-point was the difference between groups in HbA1c at the end of observation. RESULTS: A total of 610 patients were randomized: 311 to the SMBG group and 299 to the non-SMBG group. HbA1c decreased from 8.12 to 6.95% in the SMBG group and from 8.12 to 7.20% in the non-SMBG group; between-group difference was 0.25% (95% CI: 0.06, 1.03; p = 0.0097). Symptoms suggestive of mild to moderate hypoglycaemia was the most commonly reported adverse event, reported by 27 (8.7%) and 21 (7.0%) patients in the SMBG and non-SMBG groups, respectively; the incidence of symptomatic hypoglycaemia was lower in the SMBG group. CONCLUSION: In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/18494813/The_efficacy_of_self_monitoring_of_blood_glucose_in_the_management_of_patients_with_type_2_diabetes_treated_with_a_gliclazide_modified_release_based_regimen__A_multicentre_randomized_parallel_group_6_month_evaluation__DINAMIC_1_study__ L2 - https://doi.org/10.1111/j.1463-1326.2008.00894.x DB - PRIME DP - Unbound Medicine ER -